Robert Platzman, DO
Geriatric Medicine · Princeton, NJNPI 1497852966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 7.6% — the pattern of someone who eats at a lot of different presentations.
Across 110 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$147
- Acadia Pharmaceuticals Inc$139
- Pfizer$112
- Amgen$111
- AstraZeneca$103
- Lundbeck LLC$99
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$151%
- Food & beverage$1,90999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $147 |
| Acadia Pharmaceuticals Inc | 9 | $139 |
| Pfizer | 8 | $112 |
| Amgen | 7 | $111 |
| AstraZeneca | 7 | $103 |
| Lundbeck LLC | 6 | $99 |
| Johnson & Johnson | 6 | $95 |
| Alpha Cognition USA, Inc. | 2 | $93 |
| Novartis | 5 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $91 |
| Exact Sciences | 5 | $90 |
| Bayer | 5 | $88 |
| AbbVie(2 entities) | 6 | $84 |
| Lilly USA, LLC | 4 | $65 |
| Eisai Inc. | 4 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $43 |
| Boehringer Ingelheim | 3 | $39 |
| Boston Scientific | 1 | $31 |
| Merck | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| C2n Diagnostics, LLC | 1 | $24 |
| Insightec,inc | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| UCB, Inc. | 1 | $14 |
| Biogen | 1 | $14 |
| GSK | 1 | $12 |
| Kyowa Kirin, Inc. | 1 | $12 |
| Novo Nordisk | 1 | $11 |
How this compares
$1,936 in reported general payments places this provider in the 80th percentile of 165 geriatric medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 604 | $296,973 |
| XareltoRivaroxaban | 306 | $149,953 |
| NuplazidPimavanserin Tartrate | 14 | $71,231 |
| TradjentaLinagliptin | 45 | $42,917 |
| JanuviaSitagliptin Phosphate | 63 | $40,502 |
| ZenpepLipase/Protease/Amylase | 11 | $33,281 |
| AptiomEslicarbazepine Acetate | 25 | $31,415 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $31,192 |
| OzempicSemaglutide | 19 | $30,684 |
| ProcritEpoetin Alfa | 65 | $29,870 |
| PancreazeLipase/Protease/Amylase | 13 | $28,017 |
| EntrestoSacubitril/Valsartan | 43 | $25,604 |
| JardianceEmpagliflozin | 42 | $24,096 |
| XifaxanRifaximin | 12 | $23,747 |
| Atorvastatin Calcium | 1,588 | $20,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $112 | $296,973604 claims |
| Johnson & JohnsonXarelto, Procrit | $95 | $179,823371 claims |
| Acadia Pharmaceuticals IncNuplazid | $139 | $71,23114 claims |
| GSKBreo Ellipta, Anoro Ellipta, Arexvy, Trelegy Ellipta | $12 | $67,894155 claims |
| Boehringer IngelheimTradjenta, Jardiance | $39 | $67,01387 claims |
| MerckJanuvia, Lagevrio (Eua) | $28 | $57,58682 claims |
| AbbVieCreon, Vraylar, Viberzi | $84 | $31,53855 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $22 | $31,41525 claims |
| Novo NordiskOzempic | $11 | $30,68419 claims |
| NovartisEntresto | $92 | $25,60443 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $27 | $23,74712 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $19,97941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 geriatric medicine providers in New Jersey.
Other geriatric medicine in Princeton
- Albert RiddleHaworth$524K
- Gamil MakarClifton$82K
- Joshua Shua HaimManchester$45K
- Pradip ShahWest Caldwell$27K
- Gregorio GuillenPerth Amboy$8K
- Ketankumar VaidyaEdison$8K
- Cheng-An MaoClifton$8K
- Theresa RedlingLivingston$7K
- Sarita RastogiHackensack$7K
- Leslie FeiginDenville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.